Foundayo

News

Lilly's orforglipron has been approved in China, becoming the first oral GLP-1 agonist to enter the Chinese weight management market.

News

Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies sold directly on the telehealth company's platform.

News

Lilly shrugs off concerns about the effect of US drug pricing policies on its diabetes and weight loss drugs as revenues leap 39% to $24.4bn.

News

Eli Lilly's oral GLP-1 Foundayo has been recommended for weight reduction and type 2 diabetes in the EU, plus other CHMP decisions.

News

Online pharmacies operating in the UK breached Advertising Standards Authority rules by promoting oral weight drugs to the public.

News

Eli Lilly's bid to dominate the next generation of weight-loss therapies has been strengthened by data on its new combination therapy EloraTZP.